Salvatore Siena

TL;DR: The use of KRAS mutations as a selection biomarker for anti-EGFR monoclonal antibody (eg, panitumumab or cetuximab) treatment is the first major step toward individualized treatment for patients with metastatic colorectal cancer.

TL;DR: It is reported that hematopoietic progenitor cells expressing the CD34 antigen transiently circulate in the peripheral blood of cancer patients treated with 7 g/m2 cyclophosphamide (HD-CTX) with or without recombinant human granulocyte macrophage-colony stimulating factor (rHuGM-CSF).

TL;DR: The data presented in this article favor clinical use of the CD34/CD33 flow cytometry assay to guide harvesting of circulating hematopoietic progenitors for autologous transplantation and contribute to better understanding of the role played by circulating hepatopoiety progenitor cell subsets in marrow recovery after myeloablative cancer therapy.

TL;DR: Subgroup analyses support the relevance of CA 19-9 and NLR as prognostic markers in metastatic pancreatic cancer and confirm and extend the primary report of OS.

TL;DR: High-dose sequential therapy is superior to standard-dose MACOP-B for patients with diffuse large-cell lymphoma of the B-cell type and overall survival at seven years is marginally significant.